The Interventional Business Manager (iBM) Director will lead a high-performing field team responsible for driving growth and execution across the interventional glaucoma portfolio. This role is pivotal in achieving revenue targets, shaping regional business strategy, and elevating field performance within a defined U.S. area.
Working cross-functionally with Interventional Glaucoma, Corneal Health, Practice Integration, Strategic Accounts, and Market Access, the Director will ensure alignment across initiatives and foster a culture of collaboration, accountability, and results.
This position represents a critical leadership opportunity to drive growth within Glaukos. The iBM Director will shape field execution, strengthen customer partnerships, and advance our mission to deliver innovative ophthalmic solutions that improve patient care.
Key Responsibilities
- Lead, coach, and develop the iBM team to achieve and exceed area sales goals.
- Recruit, onboard, and retain top field talent.
- Partner with Area and Regional Directors to align strategic priorities and execution plans.
- Support field effectiveness through co-travel, performance coaching, and best-practice sharing.
- Build and maintain strong relationships with KOLs and key accounts.
- Oversee training and development on business reviews, practice onboarding, and customer engagement.
- Identify and address market dynamics, competitive activity, and business opportunities.
Qualifications
- Bachelor’s Degree required; advanced degree preferred.
- 10+ years of sales or marketing experience, ideally within ophthalmology or medical devices.
- Proven leadership experience managing field teams with strong results.
- Solid understanding of reimbursement, practice integration, and surgical sales.
- Excellent communication, business planning, and coaching skills.
Proficiency with CRM tools (SFDC), Excel, and PowerPoint.
-
Compensation: $157,700 – $197,100 + Variable Incentive/Bonus + RSUs
#GKOSUS
#LI-Remote
Generous. Innovative. Leadership-driven. Family-oriented. Socially responsible.
Founded in 1998, Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
Our mission at Glaukos is to truly transform vision by pioneering novel, dropless therapies that can meaningfully advance the standard of care and improve the lives of patients suffering from chronic, sight-threatening eye diseases.
Innovation is at the core of everything we do, and we are resolute in our commitment to challenge conventional thinking with new treatment alternatives that are supported by real science, robust clinical evidence, and an unrelenting focus on patients.
Our constant pursuit of game-changing technologies that disrupt legacy treatment paradigms is encapsulated in the Glaukos mantra “We’ll Go First,” which articulates our willingness to take chances, our determination to forge new ground, and our commitment to continuous improvement in all that we do.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is in Aliso Viejo, California with additional locations in San Clemente, California, and Burlington, Massachusetts.
Glaukos Corporation is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex including sexual orientation and gender identity, national origin, disability, protected Veteran Status, or any other characteristic protected by applicable federal, state, or local law.
All offers of employment are contingent upon the successful completion of a background check, including successfully passing a drug screen, based on the position and local regulations.
